1. Australia Stocks

  2. •

    Healthcare

  3. •

    Medical - Devices
Cochlear Limited

Cochlear Limited

COH.AX
Cochlear LimitedAU flagAustralian Securities Exchange
95.10
AUD
-1.64
- -
6.22BMarket Cap
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
Revenue per Share
13.23
14.14
16.25
19.78
21.85
23.71
24.73
22.14
22.78
25.06
29.44
34.11
35.81
Basic EPS, GAAP
2.33
1.65
2.56
3.31
3.9
4.27
4.8
-4
4.97
4.4
4.57
5.44
5.94
Free Cash Flow per Basic Share
0.34
1.4
2.81
2.58
3.29
-0.86
-1.99
-2.19
-1.1
-1.17
-1.46
-1.37
-1.57
Dividend per Share
2.51
2.55
2.17
2.1
2.5
2.8
3.15
3.25
1.15
2.95
3
3.75
4.25
Book Value per Share
7.01
6.35
6.7
8.11
9.7
11.21
12.85
23.29
25.01
26.33
27.46
28.57
29.85
Tangible Book Value per Share
2.13
1.67
2.23
3.92
3.55
4.62
5.23
16.62
19.76
19.66
19.84
21.2
22.15
Basic Weighted Avg Shares
57
57
57
57
57
58
58
60
66
66
66
66
65
Sales/Revenue/Turnover
753
805
926
1,131
1,254
1,364
1,427
1,321
1,498
1,648
1,936
2,236
2,343
Operating Margin (%)
21.93
12.52
18.55
19.01
22.33
22.45
21.52
11.34
15.49
17.95
16.11
18.52
17.33
Depreciation Expense
15
27
30
33
31
34
38
78
80
73
81
85
90
Net Income, GAAP
133
94
146
189
224
246
277
-238
326
289
301
357
389
Effective Tax Rate (%)
23.21
19.98
25.71
25.7
27.59
27.81
24.32
- -
10.72
26.59
24.21
26.4
25
Profit Margin (%)
17.61
11.64
15.76
16.71
17.83
18.02
19.39
-18.04
21.8
17.54
15.53
15.96
16.6
Working Capital
213
251
86
280
137
287
276
660
828
799
784
821
814
LT Debt
167
234
45
189
134
144
178
285
232
175
163
202
194
Total Equity
357
329
355
449
544
611
726
1,402
1,702
1,686
1,749
1,840
1,950
Return on Invested Capital (%)
25.26
14.56
21.93
25.67
26.51
26.72
26.97
- -
10.12
11.04
12.05
14.97
14.12
Return on Capital (%)
26.48
17.46
25.74
31.26
30.21
30.49
32.73
- -
16.85
15.17
15.41
17.63
18.45
Return on Common Equity (%)
32.93
24.66
39.26
44.73
43.86
40.93
39.93
-22.38
21.53
17.13
16.99
19.4
20.33

Capital Structure

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Working Capital

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
20.71%
7.09%
5.97%
Free Cash Flow
3.21%
-1.18%
14.25%
Net Income, GAAP
-33.25%
-43.36%
9%
Sales/Revenue/Turnover
10.02%
12.24%
4.81%
Total Cash Common Dividend
18.32%
27.02%
13.23%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
1,936
2024
- -
- -
- -
- -
2,236
2025
- -
- -
- -
- -
2,343

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
4.57
2024
- -
- -
- -
- -
5.44
2025
- -
- -
- -
- -
5.94

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
3
2024
- -
- -
- -
- -
3.75
2025
- -
- -
- -
- -
4.25

Company Description

APIChat
CEO
Diggory William Howitt
Full Time Employees
4,996
Sector
Healthcare
Industry
Medical - Devices
Address
1 University Avenue Sydney NSW Australia 2109
IPO Date
Dec 31, 1995
Website
cochlear.com
Similar Companies
Helius Medical Technologies, Inc. (HSM.TO)
AVDR US LargeCap Leading ETF (AVDR)
Nosa Plugs AB (NOSA.ST)
Echo Therapeutics, Inc. (ECTE)
Monogram Orthopaedics, Inc. (MGRM)
Deltex Medical Group plc (DTXMF)
Business
Cochlear Limited (ASX:COH) develops, manufactures and markets implantable hearing solutions worldwide, including cochlear implants, bone conduction systems and associated sound processors; the company provides the Cochlear Nucleus System, Baha System, Osia System, Kanso 3 Sound Processor, sound processor upgrades, accessories and clinical support software such as Custom Sound Pro Fitting Software and Nucleus SmartNav System. Cochlear holds approximately 60% global market share in cochlear implants and advances bimodal hearing solutions combining implants with hearing aids. Founded in 1981 and headquartered at Macquarie University in Sydney, Australia, the company operates across more than 180 countries with key revenue contributions from the Americas (49%), Europe, Middle East and Africa (35%), and Asia-Pacific (16%), employing over 5,000 people. Recent developments include the May 2024 acquisition of Oticon Medical's cochlear implant business from Demant for A$170 million, expanding its implant portfolio and customer base by over 20,000 patients; the July 2025 launch of the world's first smart cochlear implant, the Nucleus Nexa System, featuring upgradeable firmware, machine learning and AI integration; and the March 2025 expansion of its R&D partnership with GN through the Smart Hearing Alliance to accelerate AI, deep neural networks and connectivity innovations for integrated hearing solutions.

Company News

APIChat

  • gurufocus.com

    Better Hearing and Whole-Body Health: What to Know About MRI Access with Cochlear Implants